top of page


The Khismatullin lab of Tulane University, a long-time collaborator of Levisonics, has recently published the results of new research on the acoustic tweezing spectroscopy technique. The primary goal of this study was to determine if a correlation exists between the ATS technique and gold-standard lab coagulation tests – PT and aPTT. The results showed a strong correlation between the two techniques. However, the Levisonics device was tested with whole blood samples


Levisonics is honored to be recognized by the Indiana Economic Development Committee as one of the most promising early-stage startups in the state. As a result, the IEDC has included us in their 2023 Entrepreneurship Indiana yearbook, a collection of articles on exciting startups in all varieties of industries. We are proud to work in and with the state of Indiana, and we hope that we will be able to build a mutual relationship with Indiana Economic Development as we work to bring highly advanced careers to Indy through our pursuit of the future of coagulation analysis.


Levisonics is proud to be featured in the 2023 State of IoT report, published by the Indiana IoT Lab. As members and residents of the IoT lab, we find ourselves working among countless other talented and groundbreaking startups at many different stages of progression. This environment has offered us an immense amount of support and mentorship while working to advance the field of coagulation management. This article has offered us the opportunity to discuss some of the future developments we have planned to help our technology integrate with the ever-expanding Internet of Things (IoT) in healthcare. We believe that increased connectivity for diagnostic tools is helping to bring about improved outcomes for patients and physicians by eliminating wasted time and energy in healthcare. We are excited to move forward with commercializing our technology to assist in this revolution in healthcare, as the world of diagnostics moves to the web.


Levisonics is thrilled to announce that our CEO, Dr. Nithya Kasireddy, has been chosen as one of the visionary female founders for the prestigious 2023 Fellowship for Female Founders cohort. This esteemed program, hosted by the Entrepreneurship Forum (EF), is dedicated to empowering female entrepreneurs, and equipping them with essential skills for fundraising success. The fellowship has gathered 20 exceptional female founders from diverse backgrounds and regions across the United States, making it the largest cohort to date. These founders are on a mission to "Own Your Raise," learning the art of successful fundraising in the tech and innovation startup landscape. The program offers invaluable resources, including fundraising education, leadership coaching, peer support, access to investor networks, and more. Founded by The Capital Network in 2016 and adopted by EF in 2023, this initiative has already empowered 110 remarkable fellows, collectively securing over $90 million in funding for their ventures. Importantly, approximately half of these fellows represent black, indigenous, or people of color (BIPOC). Levisonics extends heartfelt congratulations to Dr. Nithya Kasireddy on her selection and acknowledges the program's Executive Director, Michelle A Moulin, and Program Director, Jingjing Li, for their dedication to its success. We invite you to join us in celebrating Dr. Nithya Kasireddy and her fellow female founders as they embark on this journey towards fundraising success. Levisonics is proud to support and celebrate female leadership in entrepreneurship! 🚀💼🌟


Levisonics Takes Stage at 2023 Gener8tor Healthcare Conference in Birmingham, AL

Levisonics is pleased to announce our dynamic presence at the Gener8tor Healthcare Conference in Birmingham, AL. Our CEO, Dr. Nithya Kasireddy, took the stage yesterday as part of the startup showcase event, seizing the opportunity to spotlight our groundbreaking innovations in blood coagulation testing. The event served as a great platform to demonstrate how Levisonics is spearheading a transformation in blood coagulation testing, making devices safer, more convenient, and comprehensive than ever before. Dr. Kasireddy's presentation showcased our commitment to advancing healthcare technology for the betterment of patients and healthcare professionals alike. Moreover, today Dr. Kasireddy participated in 1:1 lightning rounds, engaging with participants from prominent healthcare corporations and life science investors. These interactions allowed us to share our mission, foster meaningful connections, and expand our ever-growing network. Levisonics is grateful for the opportunity to make our mark at the Gener8tor Healthcare Conference, and we look forward to the positive impact that will undoubtedly follow. Stay tuned for more updates on our mission to revolutionize healthcare!


Levisonics is pleased to announce that our CEO, Dr. Nithya Kasireddy, has joined the Accelerating Innovation in Science (AXIS) mentorship program at the Indiana Biosciences Research Institute (IBRI) in downtown Indianapolis. The AXIS program provides learning entrepreneurs like Dr. Kasireddy with access to experienced mentors who offer valuable advice on growing a startup medical device business. This opportunity reflects Dr. Kasireddy's commitment to continuous learning and will contribute to Levisonics' ongoing growth and success. Stay tuned for updates as Levisonics continues to innovate in the healthcare technology sector.


Levisonics Sharpens Strategy in NIH Concept-to-Clinic Program

Levisonics is pleased to announce the successful completion of our participation in the NIH Concept-to-Clinic: Commercializing Innovation program, generously supported by the Wallace H. Coulter foundation. This program has been instrumental in refining our business strategy and advancing our mission. Our CEO Nithya Kasireddy, and her team engaged in dynamic pitch sessions with renowned industry professionals and investors specializing in biomedical innovation. These interactions proved invaluable in shaping our strategic vision. Furthermore, we continued our journey of discovery by conducting customer interviews with industry experts, uncovering unmet needs within the coagulation testing market. We extend our heartfelt gratitude to our dedicated program mentors, John Blackwood and Kathie Jordan, as well as the entire C3i team and NIH, for their unwavering support throughout this transformative experience. Levisonics remains committed to pushing boundaries and creating impactful solutions in the field of healthcare. Stay tuned for more exciting developments as we take the lessons learned from the NIH Concept-to-Clinic program into our bright future.


Levisonics is excited to announce the successful completion of our Phase 1 SBIR project, generously funded by the National Institute of Health (NIH). This project marks a pivotal step in our journey toward pioneering home-monitoring of the next generation of oral anticoagulants using our cutting-edge acoustic tweezing platform. Under the leadership of our CEO Dr. Nithya Kasireddy, who served as the Principal Investigator (PI), we have developed a minimally viable prototype designed for home-monitoring, bringing us closer to making this innovative technology accessible to individuals. The final prototype is currently housed at our collaborative laboratory at Tulane University, where our co-founder, Dr. Damir Khismatullin, will continue to oversee testing on capillary and whole blood samples generously provided by volunteers. The ongoing evaluation of device performance and the invaluable user feedback will play a significant role in refining our prototype and ensuring its practicality and effectiveness. Levisonics is deeply grateful to the NIH for their support, and we are excited to move forward with the next steps in bringing this transformative technology to life. Stay tuned for more updates as we advance in our mission to revolutionize healthcare and empower individuals with the tools for home-monitoring of oral anticoagulants.


Levisonics has achieved a resounding success at the M2D2 $200k Challenge pitch competition in Lowell, MA, showcasing our commitment to innovation and excellence. Our CEO, Nithya Kasireddy, Ph.D., recently pitched at this prestigious event, securing a spot among the top 15 finalists from a pool of highly competitive applicants. We are proud to announce that Levisonics has been honored with three invaluable in-kind awards, with a combined value of $15,000. These awards have been generously granted by distinguished organizations, including MPR Associates, Argenta Advisors, and Prime Path Medtech. These awards represent a significant milestone for Levisonics. They will play a pivotal role in accelerating our product development initiatives, as well as guiding us in the complex realms of regulatory affairs and reimbursement strategies. Additionally, these accolades offer us the opportunity to cultivate relationships with seasoned industry experts, further enhancing our expertise and network. We extend our heartfelt gratitude to M2D2 and all our supporters for this remarkable opportunity and look forward to sharing our continued progress in the exciting journey ahead. Stay tuned for more updates!


Levisonics is delighted to announce our latest achievement—an additional $50,000 in supplemental funding through the Indiana Economic Development Committee (IEDC) and Elevate Ventures. This funding bolsters our NIH Phase I SBIR grant and represents a significant milestone for our company. The supplemental funding has been granted under the state of Indiana's SBIR/STTR Grant Matching program, which supports ideation-stage Indiana companies that have received Phase 1 SBIR grants. This non-dilutive funding is a testament to the confidence and support of IEDC in Levisonics' vision and potential. We are deeply appreciative of this investment, as it will play a pivotal role in advancing our mission to shape the future of blood coagulation analysis. With these additional resources, we are better equipped to drive innovation, accelerate development, and bring transformative solutions to the field of healthcare. Levisonics extends our heartfelt thanks to IEDC and Elevate Ventures for their support. Stay tuned for exciting developments as we continue our journey of innovation and progress.


Levisonics is proud to announce our recent acceptance into the esteemed NIH Concept-to-Clinic: Commercializing Innovation (C3i) program. This marks a significant milestone in our journey as a life science startup. In this intensive boot camp, our CEO, Nithya Kasireddy, and product engineer, Jacob Parmenter, will engage in vital customer discovery interviews with healthcare professionals. They will also have the opportunity to network with industry and regulatory experts, seeking valuable feedback on presentations and materials crucial for future investors. The C3i program represents a gateway for Levisonics to refine our business strategies and navigate regulatory pathways effectively. It will enable us to plan and achieve major milestones in the company's future while strengthening our network within the industry. Levisonics is thrilled to embark on this transformative journey and looks forward to sharing the progress made during our participation in the NIH C3i program. Stay tuned for exciting updates!


Levisonics Ventures into New Horizons with Participation in NSF Regional Innovation Corps Program Hosted by Purdue University

Levisonics is delighted to share the exciting news of our selection to join the NSF's regional Innovation Corps (I-Corps) program, which is hosted by the esteemed Purdue University in West Lafayette, IN. This opportunity represents a significant step forward in our journey. Through this program, we are poised to delve deeper into the diagnostic device market, facilitating invaluable customer discovery interviews with industry professionals. We are confident that this experience will not only enrich our understanding of the market but also open doors to explore broader applications of our groundbreaking acoustic tweezing platform technology, extending far beyond its initial application in blood coagulation testing. Stay tuned as Levisonics embarks on this exciting adventure of innovation and discovery, all thanks to the NSF regional I-Corps program.


Levisonics is thrilled to announce that we have been awarded nearly $998,857 in non-dilutive funding through the NSF SBIR program, propelling us forward in our mission to innovate healthcare technology. This funding represents a substantial step in the continuation of our prior NSF project. Under the leadership of our CEO, Dr. Nithya Kasireddy, who will serve as the Principal Investigator (PI) on this project, we are poised for success. During this phase, our dedicated team will collaborate with the Fraunhofer Center for Manufacturing Innovation in Boston. Together, we aim to develop an automated sample deployment and sample containment setup for our prototype designed for small-volume blood coagulation testing. The primary objectives of this grant include the development of an automated device for sample mixing and deployment, as well as the creation of an effective method for sample containment during testing. By working closely with our collaborators at Tulane University, we intend to rigorously test and refine this innovative device. Our ultimate goal is to expedite its path to FDA approval, paving the way for a successful entry into the commercial healthcare market. Levisonics expresses profound gratitude to the NSF for their support and confidence in our vision. We look forward to the exciting developments that lie ahead as we continue our journey of innovation and progress. Stay tuned for more updates!


Levisonics is thrilled to share the exciting news of our recent achievement: the receipt of a $225,177 non-dilutive funding grant from the National Institutes of Health (NIH) through the SBIR Phase I program. This grant represents a significant milestone in our journey towards advancing healthcare technology. The NIH SBIR Phase I grant program, designed to support innovative small businesses, has granted Levisonics the opportunity to develop a groundbreaking home-use coagulation monitoring platform. This platform is dedicated to monitoring direct oral anticoagulants (DOACs), empowering patients to take charge of their health and well-being by preventing adverse drug events and enjoying life without the fear of harmful bleeding. The specific objectives of this grant are as follows: Miniaturize existing point-of-care prototypes into a user-friendly, home-use format. Develop a method for convenient finger-to-device sample delivery, facilitating testing of capillary blood samples. Validate the prototype using samples from patients undergoing oral anticoagulant treatment. As part of this visionary project, the Khismatullin lab at Tulane University will collaborate with us to collect and test capillary blood samples using the innovative prototype. Levisonics is deeply grateful to the NIH for this generous grant, which will significantly propel our mission to revolutionize coagulation monitoring. Stay tuned for more exciting updates as we continue to make a positive impact in the healthcare industry.


Levisonics is pleased to announce a significant achievement in our journey: the successful development and validation testing of our minimal viable prototype, funded through the NSF Phase 1 STTR grant. Commencing this project in early 2019, we have diligently worked towards this momentous milestone. Our minimal viable prototype represents a compact, benchtop device designed for operation by minimally trained technicians. It boasts both hardware and software capabilities to perform tests, process data, and deliver comprehensive blood coagulation profiles from blood samples. Having reached this stage, our next objective is to conduct extensive testing on clinical samples, gathering valuable feedback to refine and ultimately create our minimal marketable product. Levisonics is proud to continue pushing boundaries in the field of blood coagulation testing, and we're excited to keep you updated on our progress as we march ahead toward making a meaningful impact in healthcare.


Levisonics, in collaboration with The Khismatullin lab at Tulane University, is proud to announce the receipt of $225,000 in funding from the National Science Foundation's Small Business Technology Transfer (STTR) program. This funding represents a significant milestone in our journey toward developing a point-of-care prototype for small-volume blood coagulation testing using cutting-edge acoustic tweezing technology. With this grant, we're poised to transform our lab-based technique into a practical, commercial prototype that will undergo rigorous validation using real human blood samples at Tulane University. Our project's primary objectives include streamlining benchtop electronics into compact PCBs, integrating user-friendly test control scripts into a graphical interface, and establishing standard coagulation parameter ranges from data collected from healthy subjects. Levisonics' dedicated engineers will collaborate closely with the Fraunhofer Center for Manufacturing Innovation to bring this vision to life. This project signifies a pivotal moment for Levisonics, propelling us closer to our goal of introducing groundbreaking technology to the market. Stay tuned as we embark on this exciting journey of innovation and progress.


Levisonics is excited to announce our participation in the inaugural Accelerate South medical device accelerator program, hosted by Innovate South. This 12-week accelerator is designed to propel innovative healthcare solutions forward, and we are thrilled to be part of it. During this journey, our dedicated team at Levisonics will have the invaluable opportunity to fine-tune our business strategy, refine our marketing materials, and craft a compelling pitch tailored for healthcare investors across the southeastern region. But that's not all! We're gearing up for the Get Started Medical pitch competition, another exciting event organized by Innovate South. Among nine other impressive finalists, Levisonics will present our vision, competing for prestigious awards and garnering increased interest from healthcare investors and supporters alike. These programs are pivotal in shaping the future of our company and positioning us for success as we prepare to make our mark in the commercial healthcare market. Stay tuned for our journey ahead!


Levisonics completes NSF I-Corps Program, Paving the Way for Exciting Advances in Coagulation Testing! 🚀. Levisonics recently wrapped up our participation in the NSF Innovation Corps (I-Corps) program, and it's been an exhilarating journey. We've delved deep into the coagulation market, gaining invaluable insights into the unmet needs of healthcare professionals in coagulation testing. Through this program, our team engaged in over 120 interviews with experts from diverse backgrounds, including clinical practice, lab management, and medical device development and commercialization. The result? We've charted a clear path to revolutionize coagulation testing. Our testing platform is poised to address long-standing challenges and shortcomings in current procedures. Stay tuned for the game-changing innovations on the horizon!


Levisonics is thrilled to share that we have been selected to participate in the prestigious NSF Innovation Corps (I-Corps) program. This exciting opportunity opens new doors for Levisonics' team to explore uncharted market possibilities for our proprietary acoustic tweezing technology platform. With great enthusiasm, we are eager to advance our cutting-edge solutions, drawing upon the wealth of resources, mentorship, market insights, and the chance to engage in enlightening customer discovery interviews guided by experts in the field. As we embark on this transformative journey, we anticipate accelerated progress that will solidify our position as a true trailblazer in the industry. Stay tuned as Levisonics ventures into the future with the NSF I-Corps program, poised for innovation and discovery like never before!

bottom of page